Ординатура / Офтальмология / Английские материалы / Clinical Pathways in Glaucoma_Zimmerman, Kooner_2001

560 Index

Pituitary disease, 355–356 defined, 355

diagnosis, 356 epidemiology, 356 future, 356 treatment, 356

Plateau iris configuration, 84f, 85 Plateau iris syndrome, 84f, 85

chronic miotic therapy, 102

laser peripheral iris gonioplasty, 103 primary angle-closure glaucoma, 83–85,

84f, 102–103

POAG. See Primary open-angle glaucoma Polycythemia, 366–367 Posner-Schlossman syndrome, 162–163 Posterior polymorphous dystrophy (PPD),

129, 134–136, 138

vs. ICE syndrome, 136, 136t, 137t Posterior synechiae

pupillary block, 154, 157 Postoperative hypotony

management, 477f, 478–480, 479f Praziquantel, 387

Pregnancy, 515–530 adrenergics, 525–526 beta-antagonists, 524–525

carbonic anhydrase inhibitors, 526–527 defined, 515

diabetes mellitus, 517 diagnosis, 518–520 epidemiology, 515–518 filtering surgery, 529 fluorouracil, 529 future, 529 hyperosmotics, 528 hypertension, 517 IOP, 519–520

laser trabeculoplasty, 529 miotics, 525

mitomycin C, 529 POAG, 516, 530f prostaglandins, 527–528 treatment, 520–529, 523t visual field testing, 519

Primary angle-closure glaucoma, 81–104 chronic, 92–93

defined, 81–85 diagnosis, 89–93 epidemiology, 85–86 filtration, 103–104 future, 104 gonioscopy, 86–88, 87t hyperosmotic drugs, 93

laser iridectomy, 99–101, 100t

laser peripheral iris gonioplasty, 97 plateau iris syndrome, 83–85, 84f, 102–103 provocative testing, 89

refractive error, 86

relative pupillary block, 82, 83f

surgical iridectomy, 97–98 therapeutic corneal indentation, 95–97 treatment, 93–104, 94f–95f

vs. secondary, 81, 82t Primary congenital glaucoma, 1

gene characteristics, 9 pathology, 3–4

Primary infantile glaucoma differential diagnosis, 11 presentation, 10

Primary open-angle glaucoma (POAG), 23–51 blindness, 34

blood viscosity, 367 community-based screening, 34 CRVO, 229

defined, 23 demographics, 30–32 diagnosis of, 35–43

electrophysiologic testing, 39 epidemiology, 23–26 evaluation of, 36

exfoliation syndrome (ES), 211, 213 follow-up, 46–47

future, 50–51

geographic distribution, 26–28 glaucomatous cupping, 41 glaucomatous field defects, 41 gonioscopy, 36, 41, 43 immunologic factors, 32–33 life expectancy, 35

optic atrophy, 41 patient compliance, 46

patient counseling, 48, 50 pregnancy, 516, 530f public knowledge, 35 risk factors, 30, 30t

RP, 234

socioeconomic factors, 33 symptoms of, 35, 35t target pressure, 46 treatment, 43–50, 44f

definitive, 45–46 initial, 45

visual fields, 38–39, 42–43 vs. glaucoma suspects, 59

Pro-Banthine, 342

Progressive (essential) iris atrophy, 129–130 Prolactinomas, 355

Prolixin, 340 Promethazine HCL, 344

Propantheline bromide, 342

Propionibacterium acnes, 218 Proptosis, 120 Prostaglandin analogues, 45

contraindications, 429t NTG, 76

Prostaglandins, 428t blind, painful eye, 539 diabetes, 233

lactation, 523t pregnancy, 527–528 types, 443

uveitis glaucoma, 160 Protein kinase inhibitors, 447

Protozoan disease. See Parasitic disease Provocative testing

primary angle-closure glaucoma, 89 Prozac, 340

Pseudoexfoliation, 490, 504 Pseudoexfoliation glaucoma, 352t Pseudophakia, 214–217

angle-closure glaucoma treatment, 220

defined, 214

differential diagnosis, 215f, 216 epidemiology, 214

open-angle glaucoma, 219 pathogenesis, 214–216, 215f treatment, 217

Psoriasis, 390 Psychotropic agents, 340

Pupillary block angle closure aphakia, 216

laser iridectomy, 92, 93, 99 phacoanaphylaxis, 219 posterior synechiae, 154, 157 reverse, 177–178

vs. traumatic cataract, 288 vs. traumatic uveitis, 294 ectopia lentis, 189

treatment, 195–196 after laser iridotomy, 250

Pupils

ectopia lentis, 192 Pyrimethamine, 384

Q

Quinidine, 345

Quinine, 342

R

Race

blind, painful eye, 536–537 exfoliation syndrome, 209–210 Nevus of Ota, 405 pigmentary glaucoma, 174 POAG, 31

primary angle-closure glaucoma, 85–86 uveitic glaucoma, 164

Radiation injury, 310–311 defined, 310 diagnosis, 311

differential diagnosis, 311 epidemiology, 310 mechanism, 310 treatment, 311

Raised episcleral venous pressure, 107–126 arteriovenous anomalies, 119–123 carotid-jugular shunts, 122–123 cavernous sinus thrombosis, 118

CCSF, 119–120 classification, 107, 107t–108t

color Doppler ultrasound, 118 congestive heart failure, 117–118 defined, 107

diagnosis, 109–125, 114f–115f DSS, 122

epidemiology, 108 etiology, 113–125 filtration, 125 future, 125 genetics, 124 idiopathic, 123–124

intraorbital vascular shunts, 123 inversion therapy, 119

jugular venous obstruction, 119 laser trabeculoplasty, 125 medical evaluation, 113t ocular findings, 110t orbital-meningeal shunts, 122 orbital varices, 120–121 retrobulbar tumors, 115–116

Sturge-Weber syndrome, 121–122 thyroid ophthalmopathy, 116–117 treatment, 125

venous obstruction, 114 Ranitidine, 343

Raynaud’s phenomenon, 32–33

Red eye glaucomas. See Raised episcleral venous pressure

Refractive surgery glaucoma after, 254

Refractory glaucoma cataract, 502–503

Relative pupillary block iridectomy, 82, 83f

primary angle-closure glaucoma, 82, 83f Renal disease, 364–366

defined, 364 diagnosis, 366 epidemiology, 365 treatment, 366

Retinal cryotherapy diabetes, 233

Retinal degeneration, 234–236 defined, 234

diagnosis, 234–235 differential diagnosis, 235 epidemiology, 234 future, 236

treatment, 235–236 Retinal dystrophy, 234–236

defined, 234 diagnosis, 234–235

differential diagnosis, 235

Staurosporin, 447

Steroid-induced glaucoma, 247, 254, 258–259. See also Corticosteroid-induced glaucoma

Steroids

Behcet’s disease, 163 blind, painful eye, 539 cataract, 488

juvenile xanthogranuloma, 421–422 risk, 335, 335t

Stevens-Johnson syndrome vs. chemical injury, 309

Stickler’s syndrome diagnosis, 235

ocular hypertension, 234 treatment, 235–326

Sturge-Weber syndrome, 5, 416 raised EVP, 121–122 treatment, 422

Subacute primary angle-closure glaucoma presentation, 91–92

Succinylcholine, 342 cholinesterase inhibitors, 441

Sulfa drugs, 341–342

Superior ophthalmic vein thrombosis raised EVP, 118

Superior vena syndrome (SVCS) raised EVP, 117

Suramin, 387 Surgical iridectomy

primary angle-closure glaucoma, 97–98 Suture lysis, 476

Sweet’s syndrome, 390 Sympathetic ophthalmia, 164, 306

traumatic injury, 298

vs. phacoanaphylaxis, 218 Sympathomimetics, 344, 344t, 428t Systemic disease, 351, 352f–355f Systemic viral disease, 374–378

defined, 374 future, 378 treatment, 375f

T

Takayasu’s disease, 360 Talosa-Hunt syndrome

vs. aseptic cavernous sinus thrombosis, 118 Tenon’s cysts

needling, 481t Tetracycline, 342 Theophylline, 341 Thermal injury, 313–315

defined, 313 diagnosis, 313 epidemiology, 313 mechanism, 313 risk factors, 313 treatment, 314

Thymoxamine, 183

Index 563

acute primary angle-closure glaucoma, 96t Thyroid disease, 32, 359–360

defined, 359 diagnosis, 359 epidemiology, 359 future, 360 treatment, 359

Thyroid hormone alpha-adrenergics, 443 topical beta blockers, 435

Thyroid ophthalmopathy raised EVP, 116–117

Tiabendazole, 387 Timolol, 264

eyelid closure, 433 lactation, 523t pregnancy, 524 side effects, 434

vs. carbonic anhydrase inhibitors, 436 vs. latanoprost, 444–445

Timolol/dorzolamide, 437

Tissue plasminogen activator (TPA) hyphema, 276

Tofranil, 340

Topical beta blockers, 434 aspirin, 435

HRT, 435 NSAIDS, 435

thyroid hormone, 435

Total cholesterol (TC)/high-density lipoprotein (HDL)

beta blockers, 435

Toxocara, 388 Toxocariasis, 385

diagnosis, 387 incidence, 386

Toxoplasmosis, 379–380 diagnosis, 382 incidence, 381 treatment, 384

TPA hyphema, 276 Trabecular injury, 285–287

defined, 285 diagnosis, 286

differential diagnosis, 286–287 epidemiology, 286 mechanism, 285

treatment, 287

vs. traumatic uveitis, 295

Trabecular meshwork induced glucocorticoid response protein (TIGR), 33, 346, 357

Trabeculectomy, 17, 470–474 cataract, 474–475

failure, 161 hyphema, 276–277 indications, 467 IOP, 264

NVG, 329

uveitis glaucoma, 161

564 Index

Trabeculotomy, 17 Tranexamic acid hyphema, 276

Transpupillary cyclophotocoagulation uveitis glaucoma, 162

Tranylcypromine sulfate, 341 Trauma

blunt, 271f–272f, 282f, 289f cataracts, 199

IOP, 267t, 268–269, 274 lens capsule, 199–200 penetrating.

See Penetrating trauma. Traumatic cataracts, 287–289

defined, 287 diagnosis, 288

differential diagnosis, 288 epidemiology, 287–288 mechanism, 287 treatment, 289

vs. lens dislocation, 291 Traumatic glaucoma, 267–315 chemical injury, 307–310

defined, 267–269 electric injury, 312 future, 314–315 mechanisms, 268 nonpenetrating, 270–295 radiation injury, 310–311 sickle cell disease

treatment, 369–370 thermal injury, 313–315 treatment, 269f

Traumatic hyphema sickle cell disease, 369

Traumatic uveitis, 293–295 defined, 293–294 diagnosis, 294

differential diagnosis, 294–295 epidemiology, 294 mechanism, 293–294 treatment, 295

vs. lens dislocation, 291 vs. traumatic cataract, 288

Triamcinolone acetonide risk, 335, 335t

Tricyclic antidepressants, 340 Trifluridine, 374 Trihexyphenidyl HCL, 342 Trilafon, 340

Trypanosoma brucie, 380 Trypanosoma cruzi, 380 Tsetse fly, 380 Tube-shunt procedure

risk, 335, 335t Tube-shunt procedures

children, 18 NVG, 330

Tumors, 8

U

Ultrasound biomicroscopy (UBM) intraocular tumors, 418

Unilateral glaucoma

chronic vs. angle recession glaucoma, 284 Urea

hyphema, 276

Uveal effusion syndrome, 237–238 Uveal melanoma, 406, 420

IOP, 407t radiosurgery, 422

stereotactic radiotherapy, 422 Uveal metastasis

IOP, 407t Uveitis, 154, 352t

phacoanaphylaxis, 218 vs. electrical injury, 312

vs. ghost cell glaucoma, 281 vs. phacolytic glaucoma, 205 vs. pigmentary glaucoma, 179

Uveitis glaucoma, 155–166 corticosteroids, 158–159 cyclodestructive procedures, 161–162 cycloplegics, 160

defined, 155 diagnosis, 157–158 drainage devices, 161 elevated IOP, 157 etiology, 156 filtering surgery, 161

immunosuppressive therapy, 161 incidence, 156

miotics, 160 mydriatics, 160 NSAIDs, 160 prostaglandins, 160 race, 164

surgery, 161

treatment, 158–162, 159f Uveitis syndromes

treatment, 162–165

V

Valium, 341

Varicella-Zoster virus (VZV), 374–376 Vascular diseases, 360–362

defined, 360 diagnosis, 360 epidemiology, 360

treatment, 361–362, 361f

Vascular endothelial growth factor (VEGF), 358–359

Vascular occlusive diseases retina, 360

Verapamil, 448

EVP, 124

Viral endotheliitis, 133 Visceral leishmaniasis, 380, 381